The RNAi Market is Likely to Be Worth USD 18.6 Billion by 2030

Dec 03, 2015, 05:00 ET from Research and Markets

DUBLIN, December 3, 2015 /PRNewswire/ --

Research and Markets ( has announced the addition of the "RNAi Therapeutics Market, 2015 - 2030"  report to their offering. 

     (Logo: )

RNAi therapeutics have emerged as a new class of potent therapies capable of targeting diseases with undruggable targets. A number of disorders that are difficult to treat using traditional approaches can be addressed using this technology. 

RNAi therapeutics is characterized by a robust and opportunistic pipeline of products targeting several therapeutic areas such as oncology, genetic disorders and infectious diseases. The market has seen several collaborations between industry players aimed at the clinical and commercial development of promising candidates.

The market is predominantly being led by emerging start-ups and small companies instead of big pharma companies. Over the coming decade, this report predicts at least 11 RNAi therapies to be made commercially available. We believe the market is likely to be worth USD 18.6 billion by 2030; the overall opportunity could be much higher and depends on a number of factors such as favourable market environment, regulatory regimes and therapeutic performance of candidates in late stages of development. 

Encouraging clinical results have accelerated the progress and these therapies have emerged as one of the most effective ways of developing treatments for undruggable targets. 

The study provides an estimate of the short-midterm and long term market forecast for the period 2015 - 2030. The research, analysis and insights presented in this report include potential sales of several molecules in late (phase III, II/III) and intermediate (phase II) phases of development.

Key Topics Covered: 

1 Preface 

2 Executive Summary 

3 Introduction 

4 Market Overview 

5 Technology Platforms And Delivery Systems 

6 Regional Market 

7 Market Forecast 

8 Key Therapeutic Indications 

9 RNAi And Diagnostics 

10 Vc Funding In RNAi Therapeutics 

11 Partnerships In RNAi Therapeutics 

12 Service Providers In RNAi Therapeutics 

13 Swot Analysis 

14 Conclusion 

30 of 150+ companies mentioned in this extensive report: 

  • 4D Molecular Therapeutics
  • AbbVie
  • Abion
  • Abott Labs
  • Advirna
  • Aegerion Pharmaceuticals
  • Aligent Technologies
  • Allele Biotechnology
  • Altogen Labs
  • Alnylam Pharmaceuticals
  • Amarin
  • Ambion
  • Amgen
  • amsbio
  • AparnaBio
  • Arbutus Biopharma (previously Tekmira)
  • Archemix
  • Arcturus Therapeutics
  • Ariz Biopharma
  • Arrowhead Research Corporation
  • Artemis
  • Ascletis Pharmaceuticals
  • Asklepios
  • Astellas Pharma
  • AstraZeneca
  • Asuragen
  • Avidity NanoMedicines
  • Avocel
  • Bayer Heathcare
  • Benitec Biopharma

For more information visit

About Research and Markets:

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact: 
Laura Wood

SOURCE Research and Markets